Mirum Pharmaceuticals, Inc. (MIRM) Form 8-K — Aug 5, 2026
Mirum Pharmaceuticals reported second quarter 2026 net product sales of $176.2 million, up from $127.8 million in the year-ago quarter, led by LIVMARLI sales of $128.7 million, up 46% year over year. The company raised its full-year 2026 net product sales guidance to $680 million to $700 million. Net loss widened to $67.2 million, or $1.06 per share, from $5.9 million a year ago, as operating expenses rose to $218.8 million, including a $16.4 million acquired IPR&D charge tied to the zilurgisertib license. First-half IPR&D expense totaled $742.7 million, leaving stockholders' equity in a $10.4 million deficit at June 30, 2026.
Key figures
- Revenue
- 176243000
- Guidance
- 2026 net product sales guidance increased to $680 million to $700 million
- Total Debt
- 750079000
- Debt Amount
- 690000000
- Total Assets
- 1044981000
- Cash Position
- 561300000
- Interest Rate
- 0
- Maturity Date
- 2032
- Expand topline
- Q4 2026
- Q2 2025 revenue
- 127785000
- Q2 2026 total opex
- 218780000
- Azure 1 hdv topline
- Q3 2026
- Azure 4 hdv topline
- Q4 2026
- Vantage pbc topline
- Q1 2027
- Iprd expense h1 2026
- 742737000
- Livmarli q2 2026 sales
- 128700000
- Zilurgisertib pdufa date
- September 26, 2026
- Livmarli q2 yoy growth pct
- 46
- Weighted avg shares q2 2026
- 63374183
- Convertible notes settled 2029
- 237200000
- Bile acid medicines q2 2026 sales
- 47500000
- Bile acid medicines q2 yoy growth pct
- 20
- Iprd expense q2 zilurgisertib license
- 16435000
- Convertible notes settled pct of outstanding
- approximately 75%
Price after filing
Close on the filing date to close N calendar days later (from $104.33). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.